Table 4.
Comparison group 1 vs. group 2. The rhGH treatment: rhGH dose, height SDS, IGF1 SDS, BA/CA, (the mean value ± standard deviation score, SDS).
| Group | Number of Patients | Age at rhGH Start (Years), p < 0.05 | rhGH Dose (IU/kg/Week; mg/kg/Day) |
IGF1 SD at rhGH Start, p < 0.05 |
IGF1 SD GH1 |
IGF1 SD GH2 | BA/CA | Adrenarche Age (Years) | Central Puberty Age (Years) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 11 | 4.5 ± 3.2 | 0.53 ± 0.17; 0.025 ± 0.008 |
−0.7 ± 0.4 | 1.7 ± 1.6 | 1.7 ± 1.7 | 1.0 ± 0.2 | 6.9 ± 0.7 | 12.0 ± 2.2 * |
| 2 | 14 | 7.1 ± 2.9 | 0.50 ± 0.14; 0.024 ± 0.007 |
−1.1 ± 0.5 | 1.1 ± 1.5 | 1.3 ± 1.5 | 1.0 ± 0.1 | 10.5 ± 1.3 | 11.9 ± 1.5 ** |
RhGH: recombinant human growth hormone, IGF1: insulin-like growth factor 1, GH1: the mean time of rhGH treatment of 1.3 and 1.1 years (groups 1 and 2), GH2: the mean time of rhGH treatment of 5.9 and 6.1 years (groups 1 and 2), BA/CA: bone age/chronological age. * 8 patients, 73% of the group 1, ** 8 patients, 57% of the group 2.